Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

DC8:GR

1.751 EUR 0.188 12.03%

As of 11:20:10 ET on 03/27/2015.

Snapshot for Durect Corp (DC8)

Open: 1.527 Day's Range: 1.527 - 1.751 Volume: 5,000
Previous Close: 1.563 52wk Range: 0.531 - 1.751 1-Yr Rtn: +84.12%

Stock Chart for DC8

No chart data available.
  • DC8:GR 1.751
  • 1D
  • 1M
  • 1Y
1.563
Interactive DC8 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DC8

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.2400
Est. PEG Ratio -
Market Cap (M EUR) 199.15
Shares Outstanding (M) 113.73
30 Day Average Volume 260
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DC8

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DC8

Durect Corporation develops and commercializes pharmaceutical systems for the treatment of chronic diseases. The pharmaceutical systems provide therapy for chronic diseases or conditions by replacing multiple injection therapy or oral dosing, improving drug efficacy, reducing side effects, and ensuring dosing compliance.

Felix TheeuwesChairman/Chief Scientific OfcrJames E BrownPresident/CEO/Co-Founder
Matthew J HoganChief Financial OfficerSu Il YumExec VP:Pharmaceutical Sys
More Company Profile & Key Executives for DC8

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil